Cannabis Global Discusses its Expected 50%+ Cost Advantage
in THC-V and Other Exotic Cannabinoids for Beverage and Food
Products
LOS ANGELES,
CA -- June 03, 2020 -- InvestorsHub NewsWire -- Cannabis Global,
Inc. (OTC: MCTC)
("Cannabis Global" or the "Company"), a cannabinoid and hemp
extract science-forward company developing infusion and delivery
technologies, today provides information on
its Project Varin, a nearly complete research program implemented
to develop novel production technologies for rare cannabinoids,
including tetrahydrocannabivarin (THC-V), which is not scheduled at
the federal level.
The program has produced
meaningful technology breakthroughs, which have resulted in several
patent filings. Via these technological developments, the Company
has been able to significantly reduce the cost of exotic
cannabinoids on a per-serving basis resulting in an expected cost
advantage of greater than 50%.
"We think we have rewritten the
exotic cannabinoid cost equation via our Project Varin. The minor
exotics represent a new cost challenge for the industry, and we
believe we have developed a strong and defensible solution,"
commented Arman Tabatabaei, CEO of Cannabis Global. "Acquiring THC
and CBD from plants within the Cannabaceae family is relatively
easy as these cannabinoids are produced by nature in abundance. It
is a very different issue relative to THC-V, CBN, and other
exotics. With our patent pending technologies, we have been able to
rewrite the cost equation for minor cannabinoids, while at the same
time moving well beyond the purity possible from legacy
technologies. While we are already at a 50% cost advantage to the
competing technologies, most of which are still theoretical and not
yet available on the market, we believe further travel down our
cost curve is possible as we move into high volume manufacturing
this month."
The Company's production
technology is based on the pure THC-V. Cannabis Global expects to
establish leadership relative to quality and purity with zero heavy
metals, solvent residues, plant impurities, and no chance of
cannabinoid microbial and mold proliferation. Other manufacturing
processes require mitigation of these issues, whereas, with the
Company's technology, these simply cannot be issues as there is no
introduction of foreign substances anywhere during the
manufacturing process. The Company is moving into high volume
manufacturing for THC-V over the coming few weeks.
In addition to the utilization
of pure cannabinoids produced by state-of-the-art techniques, the
Company has completed, via its Project Varin, an ultra-efficient
production technique utilizing pharmaceutical-grade production
equipment that is just now coming to market. The combination of the
use of the pure cannabinoids, when applied to this internally
developed and now patent pending manufacturing processes, yields
what the Company believes is the most efficient exotic cannabinoid
manufacturing process in existence.
Product and technology
developments were a result of the Company's Project Varin, which
was implemented last year to invent new manufacturing and infusion
technologies for rare cannabinoids, such as THC-V. The Company
plans to utilize the developed technologies in similar applications
for other rare cannabinoids, with work on cannabinol (CBN) already
underway.
THC-V is not scheduled at the
federal level. The Company's THC-V products contain zero
tetrahydrocannabinol (THC), far below the acceptable federal level
of 0.3%, and zero heavy metals, pesticide and herbicide residues,
nitrates and other impurities that are contained in most cannabis
and hemp products. The Company's products are not intended to
diagnose, treat, cure or prevent any disease and are not for use by
or sale to persons under the age of 18. The statements made
regarding these products have not been evaluated by the Food and
Drug Administration. The efficacy of these products has not been
confirmed by FDA-approved research. These products are not intended
to diagnose, treat, cure or prevent any disease. All information
presented here is not meant as a substitute for or alternative to
information from health care practitioners. Please consult your
health care professional about potential interactions or other
possible complications before using any product.
About Cannabis Global,
Inc.
Cannabis Global, Inc., formerly
known as MCTC Holdings, Inc., is a fully audited and reporting
Company with the U.S. Securities & Exchange Commission, trading
with the stock symbol MCTC. The Company is an emerging force in the
area of cannabinoid sciences and highly bioavailable hemp and
cannabis infusion technologies. The Company does not engage in the
production, distribution, or sales of any controlled substances,
including marijuana. The Company has an actively growing portfolio
of intellectual property having filed six patents in the areas of
cannabinoid delivery systems and cannabinoid polymeric
nanoparticles. The Company markets its consumer products under the
Hemp You Can Feel brand name. Cannabis Global launched its Project
Varin early in 2020, to develop new delivery methods for rare
cannabinoid Tetrahydrocannabivarin (THC-V) and to develop products
based on this cannabinoid.
Forward-looking
Statements
This news
release contains "forward-looking statements" which are not purely
historical and may include any statements regarding beliefs, plans,
expectations or intentions regarding the future. Such
forward-looking statements include, among other things, the
development, costs and results of new business opportunities and
words such as "anticipate", "seek", intend", "believe", "estimate",
"expect", "project", "plan", or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Actual results could
differ from those projected in any forward-looking statements due
to numerous factors. Such factors include, among others, the
inherent uncertainties associated with new projects, the future
U.S. and global economies, the impact of competition, and the
Company's reliance on existing regulations regarding the use and
development of cannabis-based products. These forward-looking
statements are made as of the date of this news release, and we
assume no obligation to update the forward-looking statements, or
to update the reasons why actual results could differ from those
projected in the forward-looking statements. Although we believe
that any beliefs, plans, expectations and intentions contained in
this press release are reasonable, there can be no assurance that
any such beliefs, plans, expectations or intentions will prove to
be accurate. Investors should consult all of the information set
forth herein and should also refer to the risk factors disclosure
outlined in our annual report on Form 10-k, our quarterly reports
on Form 10-Q and other periodic reports filed from time-to-time
with the Securities and Exchange Commission. For more information,
please visit www.sec.gov.
For more
information, please contact:
Arman
Tabatabaei,
IR@cannabisglobalinc.com
+1-(310)-986-4929